New jersey

Index
Globenewswire

Will Forte Teams Up with Teva to Get Real About Huntington’s Disease with ‘Honestly HD’

Globenewswire

AJOVY® (fremanezumab-vfrm) Significantly Reduced Monthly Migraine and Headache Days in Children and Adolescents with Episodic Migraine Compared to Placebo in the SPACE Trial; Results Published in New England Journal of Medicine

Globenewswire

Impulse Dynamics® Announces New Chief Financial Officer

Globenewswire

Teva and Royalty Pharma Enter Agreement to Accelerate Development of Potential Treatment for Vitiligo

Globenewswire

Synchronoss Memamerkan Perluasan Platform Personal Cloud, Momentum Capsyl, dan Menampilkan Pratinjau Penawaran Baru di CES 2026

Globenewswire

Synchronoss Showcases Expanded Personal Cloud Platform, Capsyl Momentum, and Previews New Offering at CES 2026

Globenewswire

Verisk Ends Effort to Acquire AccuLynx

Globenewswire

DALI Alliance Meluncurkan Spesifikasi Pengujian dan Sertifikasi untuk Gateway Nirkabel ke DALI

Globenewswire

DALI Alliance Launches Test and Certification Specifications for Wireless to DALI Gateways

Globenewswire

Impulse Dynamics Completes $158M Financing Round

Globenewswire

Teva Pharmaceuticals Submits New Drug Application to FDA for Olanzapine Extended-Release Injectable Suspension (TEV-'749) for the Once-Monthly Treatment of Schizophrenia in Adults

Globenewswire

AUSTEDO® (deutetrabenazine) Tablets and AUSTEDO XR® (deutetrabenazine) Extended-release Tablets Demonstrate Positive Real-world Impact, with Patients Reporting Improvement in Involuntary Movements and Activities of Daily Living

Globenewswire

Teva Kicks Off ‘The Other TD’ to Raise Awareness of Tardive Dyskinesia (TD), with Support from Pro Football Hall of Famer Terrell Davis

Globenewswire

Impulse Dynamics® Celebrates CMS National Coverage Determination for CCM® Therapy

Globenewswire

MISTRAS Group Partnering with Villari to Offer Wireless Crack-Detection Sensors for Critical Steel Assets

Globenewswire

FDA Approves Expanded Indication for UZEDY® (risperidone) Extended-Release Injectable Suspension as a Treatment for Adults Living with Bipolar I Disorder

Globenewswire

Verisk Names Saurabh Khemka President of Underwriting Solutions

Globenewswire

Patients Taking AUSTEDO XR® (deutetrabenazine) Extended-release Tablets Reported Symptom Improvement and High Satisfaction

Globenewswire

New Long-term Safety Data from the Completed Phase 3 SOLARIS Trial Support the Potential of Olanzapine LAI (TEV-'749) as the First Long-Acting Olanzapine Treatment Option for Schizophrenia with No PDSS Observed

Globenewswire

AvePoint Announces Dual Listing on the Singapore Exchange to Continue Global Expansion

Globenewswire

AvePoint Announces Pricing of Public Offering

Globenewswire

Kyowa Kirin Announces Late-Breaking Abstract Presentation at the European Academy of Dermatology and Venerology Congress

Berita

Teva’s Emrusolmin Granted U.S. FDA Fast Track Designation for Treatment of Multiple System Atrophy

Globenewswire

$152 Billion and Rising: New Report Shows Insurance Industry Facing Growing Average Annual Losses from Natural Catastrophes

Globenewswire

Teva Announces FDA Approval and Launch of Generic Saxenda® (liraglutide injection) – First Generic GLP-1 Indicated for Weight Loss